382:. Depending on the chosen start the position of the nucleotide variant is either at position 1691 or 1746. It also affects the amino acid position for the variant, which is either 506 or 534. (Together with the general lack of nomenclature standard, this variance means that the SNP can be referred to in several ways, such as G1691A, c.1691G>A, 1691G>A, c.1746G>A, p.Arg534Gln, Arg506Gln, R506Q or rs6025.) Since this amino acid is normally the cleavage site for activated protein C, the mutation prevents efficient inactivation of factor V. When factor V remains active, it facilitates overproduction of thrombin leading to generation of excess fibrin and excess clotting.
153:
PE compared with women who do not take OCP. Women with factor V Leiden who take OCPs have about a 35-fold increased risk of developing a DVT or PE compared with women without factor V Leiden and those who do not take OCPs. Likewise, postmenopausal women taking HRT have a two- to three-fold higher risk of developing a DVT or PE than women who do not take HRT, and women with factor V Leiden who take HRT have a 15-fold higher risk. Women with heterozygous factor V Leiden who are making decisions about OCP or HRT use should take these statistics into consideration when weighing the risks and benefits of treatment.
536:), one from each parent, may have up to 80 times the usual risk of developing this type of blood clot. Considering that the risk of developing an abnormal blood clot averages about 1 in 1,000 per year in the general population, the presence of one copy of the factor V Leiden mutation increases that risk to between 3 in 1,000 to 8 in 1,000. Having two copies of the mutation may raise the risk as high as 80 in 1,000. It is unclear whether these individuals are at increased risk for
321:
579:
due to either clotting in the placenta, umbilical cord, or the fetus (fetal clotting may depend on whether the baby has inherited the gene) or influences the clotting system may have on placental development. Note that many of these women go through one or more pregnancies with no difficulties, while
454:
based test. In both methods, the time it takes for blood to clot is decreased in the presence of the factor V Leiden mutation. This is done by running two tests simultaneously; one test is run in the presence of activated protein C and the other, in the absence. A ratio is determined based on the two
152:
The use of hormones, such as oral contraceptive pills (OCPs) and hormone replacement therapy (HRT), including estrogen and estrogen-like drugs taken after menopause, increases the risk of developing DVT and PE. Healthy women taking OCPs have a three- to four-fold increased risk of developing a DVT or
117:
The symptoms of factor V Leiden vary among individuals. There are some individuals who have the F5 gene and who never develop thrombosis, while others have recurring thrombosis before the age of 30 years. This variability is influenced by the number of F5 gene (chromosome 1) mutations a person has,
79:, an anticoagulant protein that normally inhibits the pro-clotting activity of factor V, is not able to bind normally to factor V, leading to a hypercoagulable state, i.e., an increased tendency for the patient to form abnormal and potentially harmful blood clots. Factor V Leiden is the most common
445:
Suspicion of factor V Leiden being the cause for any thrombotic event should be considered in any
Caucasian patient below the age of 45, or in any person with a family history of venous thrombosis. There are a few different methods by which this condition can be diagnosed. Most laboratories screen
518:
Studies have found that about 5 percent of
Caucasians in North America have factor V Leiden. Data have indicated that prevalence of factor V Leiden is greater among Caucasians than minority Americans. One study also suggested "that the factor VâLeiden mutation segregates in populations with
1680:
1668:
1653:
455:
tests and the results signify to the laboratory whether activated protein C is working or not. There is also a genetic test that can be done for this disorder. The mutation (a 1691GâA substitution) removes a cleavage site of the
527:
have this condition. The risk of developing a clot in a blood vessel depends on whether a person inherits one or two copies of the factor V Leiden mutation. Inheriting one copy of the mutation from a parent
1756:
498:
in people with factor V Leiden warrants temporary anticoagulant treatment, but generally not lifelong treatment. In addition, temporary treatment with an anticoagulant such as
338:, i.e. not every person who has the mutation develops the disease. The condition results in a factor V variant that cannot be as easily degraded by activated protein C. The
706:
Ridker PM, Miletich JP, Hennekens CH, Buring JE (1997). "Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening".
91:, where it was first identified in 1994 by Rogier Maria Bertina under the direction of (and in the laboratory of) Pieter Hendrick Reitsma. Despite the increased risk of
1053:
567:-containing birth control pills or hormone replacement) in the form of deep vein thrombosis and pulmonary embolism. They also may have a small increased risk of
1749:
118:
the presence of other gene alterations related to blood clotting, and circumstantial risk factors, such as surgery, use of oral contraceptives and pregnancy.
1524:
1486:
819:
Bertina RM, Koeleman BP, Koster T, et al. (May 1994). "Mutation in blood coagulation factor V associated with resistance to activated protein C".
1484:
Andreassi MG, Botto N, Maffei S (2006). "Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening".
1742:
1336:"Comparison of Russell viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C"
1873:
1370:
956:
1603:
741:
Gregg JP, Yamane AJ, Grody WW (December 1997). "Prevalence of the factor V-Leiden mutation in four distinct
American ethnic populations".
447:
926:
754:
2048:
2031:
1695:
611:"Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease"
519:
significant
Caucasian admixture and is rare in genetically distant nonâEuropean groups." Up to 30 percent of patients who present with
490:
factor V Leiden, unless there are additional risk factors present, but are given when such an event occurs. A single occurrence of
2110:
2062:
610:
1294:
Rodger MA, Paidas M, McLintock C, et al. (August 2008). "Inherited thrombophilia and pregnancy complications revisited".
1829:
355:
2116:
267:
955:
Juul, Klaus; TybjÌrg-Hansen, Anne; Steffensen, Rolf; Kofoed, Steen; Jensen, Gorm; Nordestgaard, Børge Grønne (2002-07-01).
2371:
2102:
580:
others may repeatedly have pregnancy complications, and still others may develop clots within weeks of becoming pregnant.
2090:
2053:
544:
individuals have a more severe clinical condition. The presence of acquired risk factors for venous thrombosisâincluding
1923:
1280:
506:
factor V Leiden or heterozygous factor V Leiden with additional thrombophilia however should be considered for lifelong
1560:
2243:
1819:
532:) increases by fourfold to eightfold the chance of developing a clot. People who inherit two copies of the mutation (
474:
will give a diagnosis. Other PCR based assays such as iPLEX can also identify zygosity and frequency of the variant.
1569:
540:
venous thrombosis. While only 1 percent of people with factor V Leiden have two copies of the defective gene, these
95:, people with one copy of this gene have not been found to have shorter lives than the general population. It is an
2198:
2043:
1371:"Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders"
2314:
1885:
1866:
776:
De
Stefano V, Chiusolo P, Paciaroni K, Leone G (1998). "Epidemiology of factor V Leiden: clinical implications".
463:
418:
177:
2284:
2027:
1856:
1706:
1595:
1447:
Nicolaes GA, Dahlbäck B (April 2002). "Factor V and thrombotic disease: description of a janus-faced protein".
456:
2067:
2381:
2376:
2274:
277:
502:
may be required during periods of particularly high risk of thrombosis, such as major surgery. People with
2188:
2163:
2121:
549:
402:
92:
1625:
676:
2183:
2173:
1991:
414:
363:
677:"Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia"
239:
409:. It is extremely rare for this disorder to cause the formation of clots in arteries that can lead to
215:
1939:
1834:
1824:
1662:
828:
520:
491:
422:
390:
126:
99:
556:âfurther increase the chance that an individual with the factor V Leiden mutation will develop DVT.
2178:
2168:
1964:
1844:
1684:
589:
507:
471:
2304:
1986:
1791:
1552:
1511:
1472:
994:
852:
801:
571:, may have a small increased risk of low birth weight babies, may have a small increased risk of
524:
495:
406:
331:
130:
72:
1944:
1918:
1611:
71:(one of several substances that helps blood clot), which causes an increase in blood clotting (
2193:
1969:
1878:
1717:
1577:
1544:
1503:
1464:
1435:
1390:
1357:
1311:
1205:
1165:
1147:
1106:
1098:
1035:
986:
978:
934:
893:
844:
793:
758:
723:
688:
643:
38:
1014:"LESSON OF THE MONTH â Catastrophic Arterial Thromboembolism Associated with Factor V Leiden"
2019:
1959:
1954:
1814:
1536:
1495:
1456:
1425:
1415:
1382:
1347:
1303:
1197:
1155:
1137:
1088:
1025:
968:
911:
883:
836:
785:
750:
715:
633:
625:
262:
102:
1591:
1243:"Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations".
393:(DVT). If the venous clots break off, these clots can travel through the right side of the
2299:
2133:
609:
Klarin D, Busenkell E, Judy R, Lynch J, Levin M, Haessler J, et al. (November 2019).
545:
1974:
482:
As there is no cure yet, treatment is focused on prevention of thrombotic complications.
227:
832:
17:
2324:
2036:
1979:
1861:
1689:
1460:
1188:
Nichols WL, Heit JA (September 1996). "Activated protein C resistance and thrombosis".
1160:
1125:
1093:
1076:
638:
385:
The excessive clotting that occurs in this disorder is almost always restricted to the
2365:
2334:
2156:
2151:
2146:
1903:
1734:
1430:
1403:
483:
312:
139:
Having venous thrombosis in unusual sites in the body such as the brain or the liver.
1556:
1515:
1476:
805:
651:
2344:
1786:
998:
856:
568:
529:
487:
434:
194:
1711:
1386:
1307:
888:
871:
251:
2141:
1949:
1781:
1770:
572:
285:
145:
Having a history of unexplained pregnancy loss in the second or third trimester.
1126:"Assessing the risk of recurrent venous thromboembolism â a practical approach"
973:
303:, which polymerizes to form the dense meshwork that makes up the majority of a
2329:
2294:
2269:
1913:
1895:
925:
Jennifer
Bushwitz; Michael A. Pacanowski & Julie A. Johnson (2006-10-11).
629:
576:
559:
Women with factor V Leiden have a substantially increased risk of clotting in
541:
533:
503:
426:
371:
335:
320:
315:
that acts to limit the extent of clotting by cleaving and degrading factor V.
296:
189:
106:
80:
43:
1722:
1352:
1335:
1151:
1102:
982:
719:
2319:
2264:
1851:
755:
10.1002/(SICI)1096-8628(19971219)73:3<334::AID-AJMG20>3.0.CO;2-J
560:
433:
are at a heightened risk for the events detailed above versus those who are
379:
308:
281:
76:
1581:
1548:
1507:
1468:
1439:
1394:
1361:
1315:
1169:
1110:
1039:
1030:
1013:
990:
897:
647:
1499:
1209:
1124:
Keo, Hong H; Fahrni, Jennifer; Husmann, Marc; Gretener, Silvia B. (2015).
848:
797:
789:
762:
727:
692:
2233:
2228:
2218:
2077:
1908:
1766:
1540:
930:
564:
375:
347:
292:
182:
148:
Having a DVT or PE and a strong family history of venous thromboembolism.
96:
68:
1142:
2279:
2238:
553:
499:
367:
246:
210:
84:
1645:
957:"Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses"
2223:
1672:
1657:
1201:
840:
430:
410:
300:
289:
234:
88:
1268:
1525:"Coagulation factor V and thrombophilia: background and mechanisms"
1420:
1334:
Herskovits AZ, Lemire SJ, Longtine J, Dorfman DM (November 2008).
1267:
What do we know about heredity and factor V Leiden thrombophilia?
394:
386:
319:
222:
1568:
Kujovich J; Pagon, RA; Bird, TC; Dolan, CR; Stephens, K (2010) .
1700:
1226:"Ethnic distribution of factor V Leiden in 4047 men and women".
451:
398:
359:
351:
339:
304:
1738:
87:
amongst ethnic
Europeans. It is named after the Dutch city of
1404:"The relationship between FV Leiden and pulmonary embolism"
1369:
Press RD, Bauer KA, Kujovich JL, Heit JA (November 2002).
1012:
Ng, N; Brown, JRI; Edmondson, RA; Tillyer, Ml (May 2000).
1070:
1068:
1066:
1281:"Factor V Leiden thrombophilia: MedlinePlus Genetics"
1018:
European
Journal of Vascular and Endovascular Surgery
1635:
1626:
1523:
Segers K, Dahlbäck B, Nicolaes GA (September 2007).
2254:
2211:
2132:
2076:
2018:
2011:
2004:
1932:
1894:
1807:
1800:
1639:
1610:. University of Washington, Seattle. Archived from
446:'at risk' patients with either a snake venom (e.g.
421:, is more common. Given that this disease displays
261:
245:
233:
221:
209:
200:
188:
176:
168:
163:
142:
Having a DVT or PE during or right after pregnancy.
37:
32:
1449:Arteriosclerosis, Thrombosis, and Vascular Biology
548:, use of estrogen-containing (combined) forms of
366:of amino acid R to amino acid Q, it changes the
324:Pathophysiology of factor V Leiden gene mutation
1375:Archives of Pathology & Laboratory Medicine
276:In the normal pathway, factor V functions as a
1183:
1181:
1179:
486:are not routinely recommended for people with
1750:
8:
1075:Ornstein, Deborah L.; Cushman, Mary (2003).
334:genetic condition that exhibits incomplete
2015:
2008:
1804:
1757:
1743:
1735:
1636:
1487:Clinical Chemistry and Laboratory Medicine
29:
1594:at the U.S. National Library of Medicine
1429:
1419:
1351:
1159:
1141:
1092:
1029:
972:
887:
637:
342:that codes the protein is referred to as
172:Factor V Leiden, Arg506Gln, R506Q, G1691A
1602:Kujovich JL, Goodnight SH (2007-02-17).
1054:"Factor V Leiden Mutation â Homozygous"
601:
83:hypercoagulability (prone to clotting)
67:) is a variant (mutated form) of human
1340:American Journal of Clinical Pathology
927:"Important Variant Information for F5"
160:
778:Seminars in Thrombosis and Hemostasis
417:, though a "mini-stroke", known as a
121:Symptoms of factor V Leiden include:
7:
743:American Journal of Medical Genetics
1130:Vascular Health and Risk Management
133:(pulmonary embolism) before age 50.
1461:10.1161/01.ATV.0000012665.51263.B7
1094:10.1161/01.CIR.0000068167.08920.F1
25:
1402:Hooper WC, De Staercke C (2002).
1269:http://www.genome.gov/15015167#Q5
448:dilute Russell's viper venom time
389:, where the clotting may cause a
2111:platelet storage pool deficiency
2063:Heparin-induced thrombocytopenia
1604:"Factor V Leiden Thrombophilia"
1570:"Factor V Leiden Thrombophilia"
872:"Factor V Leiden thrombophilia"
1830:Activated protein C resistance
675:De Stefano V, Leone G (1995).
356:single nucleotide polymorphism
1:
33:Factor V Leiden thrombophilia
1924:Trousseau sign of malignancy
1387:10.5858/2002-126-1304-CUOFVL
1308:10.1097/AOG.0b013e31817e8acc
889:10.1097/GIM.0b013e3181faa0f2
870:Kujovich JL (January 2011).
2244:Nonthrombocytopenic purpura
1820:Antithrombin III deficiency
295:. Thrombin in turn cleaves
136:Having recurring DVT or PE.
2398:
2199:Congenital afibrinogenemia
2103:Glanzmann's thrombasthenia
1529:Thrombosis and Haemostasis
974:10.1182/blood-2002-01-0111
129:(deep vein thrombosis) or
2315:Gastrointestinal bleeding
2117:HermanskyâPudlak syndrome
1886:Antiphospholipid syndrome
1867:Essential thrombocythemia
1777:
1296:Obstetrics and Gynecology
630:10.1038/s41588-019-0519-3
419:transient ischemic attack
257:
205:
75:). Due to this mutation,
2285:Subconjunctival bleeding
2091:BernardâSoulier syndrome
2054:UpshawâSchulman syndrome
2028:Thrombocytopenic purpura
1857:Sticky platelet syndrome
1596:Medical Subject Headings
1353:10.1309/AJCP7YBJ6URTVCWP
720:10.1001/jama.277.16.1305
457:restriction endonuclease
18:Factor V Leiden mutation
2275:Intracranial hemorrhage
912:"SNP linked to Gene F5"
93:venous thromboembolisms
2189:Factor XIII deficiency
2169:Hypoprothrombinemia/II
2164:von Willebrand disease
2122:Gray platelet syndrome
1031:10.1053/ejvs.1999.0971
550:hormonal contraception
403:pulmonary blood vessel
330:Factor V Leiden is an
325:
2184:Factor XII deficiency
2174:Factor VII deficiency
1992:Renal vein thrombosis
1500:10.1515/CCLM.2006.103
790:10.1055/s-2007-996025
364:missense substitution
323:
2372:SNPs on chromosome 1
1940:Deep vein thrombosis
1835:Protein S deficiency
1825:Protein C deficiency
1541:10.1160/th07-02-0150
1408:Respiratory Research
876:Genetics in Medicine
521:deep vein thrombosis
492:deep vein thrombosis
423:incomplete dominance
391:deep vein thrombosis
358:(SNP) is located in
2179:Factor X deficiency
2068:MayâHegglin anomaly
1845:Prothrombin G20210A
1143:10.2147/VHRM.S83718
833:1994Natur.369...64B
590:Prothrombin G20210A
472:DNA electrophoresis
450:) based test or an
401:where they block a
288:, resulting in the
2305:Pulmonary hematoma
2212:Signs and symptoms
1987:Pulmonary embolism
1792:Bleeding diathesis
1302:(2 Pt 1): 320â24.
525:pulmonary embolism
496:pulmonary embolism
437:for the mutation.
407:pulmonary embolism
332:autosomal dominant
326:
201:External databases
113:Signs and symptoms
73:hypercoagulability
2359:
2358:
2355:
2354:
2207:
2206:
2194:Dysfibrinogenemia
2078:Platelet function
2000:
1999:
1879:Purpura fulminans
1732:
1731:
1077:"Factor V Leiden"
624:(11): 1574â1579.
510:anticoagulation.
466:, treatment with
273:
272:
49:
48:
27:Medical condition
16:(Redirected from
2389:
2020:Thrombocytopenia
2016:
2009:
1965:Lowenberg's sign
1815:Clotting factors
1805:
1759:
1752:
1745:
1736:
1637:
1622:
1620:
1619:
1585:
1564:
1559:. Archived from
1519:
1480:
1443:
1433:
1423:
1398:
1365:
1355:
1320:
1319:
1291:
1285:
1284:
1277:
1271:
1265:
1259:
1254:
1248:
1237:
1231:
1220:
1214:
1213:
1202:10.4065/71.9.897
1185:
1174:
1173:
1163:
1145:
1121:
1115:
1114:
1096:
1072:
1061:
1060:
1058:
1050:
1044:
1043:
1033:
1009:
1003:
1002:
976:
952:
946:
945:
943:
942:
933:. Archived from
922:
916:
915:
908:
902:
901:
891:
867:
861:
860:
841:10.1038/369064a0
816:
810:
809:
773:
767:
766:
738:
732:
731:
703:
697:
696:
672:
666:
665:
663:
662:
656:
650:. Archived from
641:
615:
606:
429:for the mutated
425:, those who are
161:
105:with incomplete
103:genetic disorder
30:
21:
2397:
2396:
2392:
2391:
2390:
2388:
2387:
2386:
2362:
2361:
2360:
2351:
2300:Hemopericardium
2250:
2203:
2134:Clotting factor
2128:
2072:
1996:
1945:Bancroft's sign
1928:
1919:Virchow's triad
1890:
1840:Factor V Leiden
1796:
1773:
1763:
1733:
1728:
1727:
1648:
1634:
1617:
1615:
1601:
1592:factor+V+Leiden
1588:
1567:
1522:
1483:
1446:
1401:
1381:(11): 1304â18.
1368:
1333:
1329:
1327:Further reading
1324:
1323:
1293:
1292:
1288:
1279:
1278:
1274:
1266:
1262:
1255:
1251:
1238:
1234:
1221:
1217:
1187:
1186:
1177:
1123:
1122:
1118:
1074:
1073:
1064:
1056:
1052:
1051:
1047:
1011:
1010:
1006:
954:
953:
949:
940:
938:
924:
923:
919:
910:
909:
905:
869:
868:
864:
818:
817:
813:
775:
774:
770:
740:
739:
735:
705:
704:
700:
674:
673:
669:
660:
658:
654:
618:Nature Genetics
613:
608:
607:
603:
598:
586:
516:
480:
443:
275:
159:
157:Pathophysiology
125:Having a first
115:
52:Factor V Leiden
28:
23:
22:
15:
12:
11:
5:
2395:
2393:
2385:
2384:
2382:Coagulopathies
2379:
2377:Blood proteins
2374:
2364:
2363:
2357:
2356:
2353:
2352:
2350:
2349:
2348:
2347:
2339:
2338:
2337:
2332:
2327:
2325:Hemoperitoneum
2322:
2317:
2309:
2308:
2307:
2302:
2297:
2289:
2288:
2287:
2282:
2277:
2272:
2267:
2258:
2256:
2252:
2251:
2249:
2248:
2247:
2246:
2236:
2231:
2226:
2221:
2215:
2213:
2209:
2208:
2205:
2204:
2202:
2201:
2196:
2191:
2186:
2181:
2176:
2171:
2166:
2161:
2160:
2159:
2154:
2149:
2138:
2136:
2130:
2129:
2127:
2126:
2125:
2124:
2119:
2107:
2106:
2105:
2095:
2094:
2093:
2082:
2080:
2074:
2073:
2071:
2070:
2065:
2059:
2058:
2057:
2056:
2051:
2041:
2040:
2039:
2037:Evans syndrome
2024:
2022:
2013:
2006:
2002:
2001:
1998:
1997:
1995:
1994:
1989:
1984:
1983:
1982:
1977:
1972:
1970:Peabody's sign
1967:
1962:
1957:
1952:
1947:
1936:
1934:
1930:
1929:
1927:
1926:
1921:
1916:
1911:
1906:
1900:
1898:
1892:
1891:
1889:
1888:
1883:
1882:
1881:
1871:
1870:
1869:
1864:
1862:Thrombocytosis
1859:
1849:
1848:
1847:
1842:
1837:
1832:
1827:
1822:
1811:
1809:
1802:
1798:
1797:
1795:
1794:
1789:
1784:
1778:
1775:
1774:
1764:
1762:
1761:
1754:
1747:
1739:
1730:
1729:
1726:
1725:
1714:
1703:
1692:
1677:
1665:
1649:
1644:
1643:
1641:
1640:Classification
1633:
1632:External links
1630:
1629:
1628:
1623:
1599:
1587:
1586:
1565:
1563:on 2013-02-11.
1520:
1481:
1444:
1399:
1366:
1346:(5): 796â804.
1330:
1328:
1325:
1322:
1321:
1286:
1272:
1260:
1249:
1232:
1215:
1190:Mayo Clin Proc
1175:
1116:
1062:
1045:
1024:(5): 551â553.
1004:
947:
917:
903:
862:
827:(6475): 64â7.
811:
768:
733:
714:(16): 1305â7.
698:
667:
600:
599:
597:
594:
593:
592:
585:
582:
515:
512:
484:Anticoagulants
479:
476:
442:
439:
328:
327:
271:
270:
265:
259:
258:
255:
254:
249:
243:
242:
237:
231:
230:
225:
219:
218:
213:
207:
206:
203:
202:
198:
197:
192:
186:
185:
180:
174:
173:
170:
166:
165:
158:
155:
150:
149:
146:
143:
140:
137:
134:
114:
111:
47:
46:
41:
35:
34:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
2394:
2383:
2380:
2378:
2375:
2373:
2370:
2369:
2367:
2346:
2343:
2342:
2340:
2336:
2335:Hematosalpinx
2333:
2331:
2328:
2326:
2323:
2321:
2318:
2316:
2313:
2312:
2310:
2306:
2303:
2301:
2298:
2296:
2293:
2292:
2290:
2286:
2283:
2281:
2278:
2276:
2273:
2271:
2268:
2266:
2263:
2262:
2260:
2259:
2257:
2253:
2245:
2242:
2241:
2240:
2237:
2235:
2232:
2230:
2227:
2225:
2222:
2220:
2217:
2216:
2214:
2210:
2200:
2197:
2195:
2192:
2190:
2187:
2185:
2182:
2180:
2177:
2175:
2172:
2170:
2167:
2165:
2162:
2158:
2155:
2153:
2150:
2148:
2145:
2144:
2143:
2140:
2139:
2137:
2135:
2131:
2123:
2120:
2118:
2115:
2114:
2113:
2112:
2108:
2104:
2101:
2100:
2099:
2096:
2092:
2089:
2088:
2087:
2084:
2083:
2081:
2079:
2075:
2069:
2066:
2064:
2061:
2060:
2055:
2052:
2050:
2047:
2046:
2045:
2042:
2038:
2035:
2034:
2033:
2029:
2026:
2025:
2023:
2021:
2017:
2014:
2010:
2007:
2003:
1993:
1990:
1988:
1985:
1981:
1978:
1976:
1973:
1971:
1968:
1966:
1963:
1961:
1960:Louvel's sign
1958:
1956:
1955:Lisker's sign
1953:
1951:
1948:
1946:
1943:
1942:
1941:
1938:
1937:
1935:
1931:
1925:
1922:
1920:
1917:
1915:
1912:
1910:
1907:
1905:
1904:Thrombophilia
1902:
1901:
1899:
1897:
1893:
1887:
1884:
1880:
1877:
1876:
1875:
1872:
1868:
1865:
1863:
1860:
1858:
1855:
1854:
1853:
1850:
1846:
1843:
1841:
1838:
1836:
1833:
1831:
1828:
1826:
1823:
1821:
1818:
1817:
1816:
1813:
1812:
1810:
1806:
1803:
1799:
1793:
1790:
1788:
1785:
1783:
1780:
1779:
1776:
1772:
1768:
1765:Disorders of
1760:
1755:
1753:
1748:
1746:
1741:
1740:
1737:
1724:
1720:
1719:
1715:
1713:
1709:
1708:
1704:
1702:
1698:
1697:
1693:
1691:
1687:
1686:
1682:
1678:
1675:
1674:
1670:
1666:
1664:
1660:
1659:
1655:
1651:
1650:
1647:
1642:
1638:
1631:
1627:
1624:
1614:on 2008-06-02
1613:
1609:
1605:
1600:
1597:
1593:
1590:
1589:
1583:
1579:
1575:
1571:
1566:
1562:
1558:
1554:
1550:
1546:
1542:
1538:
1535:(3): 530â42.
1534:
1530:
1526:
1521:
1517:
1513:
1509:
1505:
1501:
1497:
1494:(5): 514â21.
1493:
1489:
1488:
1482:
1478:
1474:
1470:
1466:
1462:
1458:
1454:
1450:
1445:
1441:
1437:
1432:
1427:
1422:
1421:10.1186/rr180
1417:
1413:
1409:
1405:
1400:
1396:
1392:
1388:
1384:
1380:
1376:
1372:
1367:
1363:
1359:
1354:
1349:
1345:
1341:
1337:
1332:
1331:
1326:
1317:
1313:
1309:
1305:
1301:
1297:
1290:
1287:
1282:
1276:
1273:
1270:
1264:
1261:
1258:
1253:
1250:
1246:
1242:
1236:
1233:
1229:
1225:
1219:
1216:
1211:
1207:
1203:
1199:
1195:
1191:
1184:
1182:
1180:
1176:
1171:
1167:
1162:
1157:
1153:
1149:
1144:
1139:
1135:
1131:
1127:
1120:
1117:
1112:
1108:
1104:
1100:
1095:
1090:
1087:(15): e94-7.
1086:
1082:
1078:
1071:
1069:
1067:
1063:
1055:
1049:
1046:
1041:
1037:
1032:
1027:
1023:
1019:
1015:
1008:
1005:
1000:
996:
992:
988:
984:
980:
975:
970:
966:
962:
958:
951:
948:
937:on 2011-07-27
936:
932:
928:
921:
918:
913:
907:
904:
899:
895:
890:
885:
881:
877:
873:
866:
863:
858:
854:
850:
846:
842:
838:
834:
830:
826:
822:
815:
812:
807:
803:
799:
795:
791:
787:
784:(4): 367â79.
783:
779:
772:
769:
764:
760:
756:
752:
748:
744:
737:
734:
729:
725:
721:
717:
713:
709:
702:
699:
694:
690:
687:(4): 344â56.
686:
682:
681:Haematologica
678:
671:
668:
657:on 2020-01-28
653:
649:
645:
640:
635:
631:
627:
623:
619:
612:
605:
602:
595:
591:
588:
587:
583:
581:
578:
574:
570:
566:
562:
557:
555:
552:, and recent
551:
547:
543:
539:
535:
531:
526:
522:
513:
511:
509:
505:
501:
497:
493:
489:
485:
477:
475:
473:
469:
465:
461:
458:
453:
449:
440:
438:
436:
432:
428:
424:
420:
416:
412:
408:
404:
400:
396:
392:
388:
383:
381:
377:
373:
369:
365:
361:
357:
353:
349:
345:
341:
337:
333:
322:
318:
317:
316:
314:
313:anticoagulant
311:is a natural
310:
306:
302:
298:
294:
291:
287:
283:
279:
269:
266:
264:
260:
256:
253:
250:
248:
244:
241:
238:
236:
232:
229:
226:
224:
220:
217:
216:Human SNPView
214:
212:
208:
204:
199:
196:
193:
191:
187:
184:
181:
179:
175:
171:
167:
162:
156:
154:
147:
144:
141:
138:
135:
132:
128:
124:
123:
122:
119:
112:
110:
108:
104:
101:
98:
94:
90:
86:
82:
78:
74:
70:
66:
63:
62:
57:
53:
45:
42:
40:
36:
31:
19:
2345:Hemarthrosis
2109:
2097:
2085:
1975:Pratt's sign
1839:
1787:coagulopathy
1716:
1705:
1694:
1679:
1667:
1652:
1616:. Retrieved
1612:the original
1607:
1573:
1561:the original
1532:
1528:
1491:
1485:
1455:(4): 530â8.
1452:
1448:
1411:
1407:
1378:
1374:
1343:
1339:
1299:
1295:
1289:
1275:
1263:
1256:
1252:
1244:
1240:
1235:
1227:
1223:
1218:
1196:(9): 897â8.
1193:
1189:
1133:
1129:
1119:
1084:
1080:
1048:
1021:
1017:
1007:
964:
960:
950:
939:. Retrieved
935:the original
920:
906:
879:
875:
865:
824:
820:
814:
781:
777:
771:
749:(3): 334â6.
746:
742:
736:
711:
707:
701:
684:
680:
670:
659:. Retrieved
652:the original
621:
617:
604:
569:preeclampsia
558:
537:
530:heterozygous
517:
514:Epidemiology
488:heterozygous
481:
467:
459:
444:
435:heterozygous
415:heart attack
405:and cause a
384:
343:
329:
307:. Activated
284:to activate
274:
151:
120:
116:
64:
60:
59:
55:
51:
50:
2098:aggregation
1980:Rose's sign
1950:Homans sign
1782:Coagulation
1608:GeneReviews
1574:GeneReviews
1081:Circulation
967:(1): 3â10.
882:(1): 1â16.
573:miscarriage
470:, and then
286:prothrombin
164:SNP: rs6025
2366:Categories
2330:Hematocele
2295:Hemothorax
2270:Hemoptysis
2142:Hemophilia
1914:Thrombosis
1718:DiseasesDB
1618:2008-06-20
941:2008-09-10
661:2020-01-28
596:References
577:stillbirth
542:homozygous
534:homozygous
504:homozygous
478:Management
427:homozygous
372:amino acid
336:penetrance
297:fibrinogen
190:Chromosome
107:penetrance
81:hereditary
44:Hematology
2320:Hemobilia
2265:Epistaxis
1852:Platelets
1152:1178-2048
1136:: 451â9.
1103:0009-7322
983:1528-0020
561:pregnancy
538:recurrent
523:(DVT) or
441:Diagnosis
380:glutamine
362:10. As a
309:protein C
282:factor Xa
280:to allow
268:SI001216K
97:autosomal
77:protein C
39:Specialty
2311:abdomen
2234:Petechia
2229:Hematoma
2219:Bleeding
2086:adhesion
2012:By cause
2005:Bleeding
1909:Thrombus
1808:By cause
1801:Clotting
1771:clotting
1767:bleeding
1676:: D68.51
1582:20301542
1557:29406966
1549:17849041
1516:34399027
1508:16681418
1477:13215200
1469:11950687
1440:11806843
1414:(1): 8.
1395:12421138
1362:18854273
1316:18669729
1222:Ridker,
1170:26316770
1111:12707252
1040:10828239
991:12070000
931:PharmGKB
898:21116184
806:45534038
648:31676865
584:See also
565:estrogen
563:(and on
376:arginine
350:of this
348:Mutation
299:to form
293:thrombin
278:cofactor
183:Factor V
100:dominant
85:disorder
69:factor V
2280:Hyphema
2255:By site
2239:Purpura
1933:By site
1712:C095381
1663:3B61.0Y
1239:Gregg,
1210:8790269
1161:4544622
999:9556602
914:. NCBI.
857:4314040
849:8164741
829:Bibcode
798:9763354
763:9415695
728:9109469
693:7590506
639:6858581
554:surgery
546:smoking
500:heparin
397:to the
368:protein
247:SNPedia
211:Ensembl
169:Name(s)
65:p.R506Q
2341:joint
2291:torso
2224:Bruise
2147:A/VIII
1701:188055
1690:289.81
1598:(MeSH)
1580:
1555:
1547:
1514:
1506:
1475:
1467:
1438:
1428:
1393:
1360:
1314:
1241:et al.
1224:et al.
1208:
1168:
1158:
1150:
1109:
1101:
1038:
997:
989:
981:
896:
855:
847:
821:Nature
804:
796:
761:
726:
691:
646:
636:
431:allele
411:stroke
301:fibrin
290:enzyme
263:ALFRED
235:HapMap
89:Leiden
56:rs6025
2261:head
1896:Clots
1553:S2CID
1512:S2CID
1473:S2CID
1431:64819
1245:Supra
1228:Supra
1057:(PDF)
995:S2CID
961:Blood
853:S2CID
802:S2CID
655:(PDF)
614:(PDF)
462:, so
395:heart
387:veins
374:from
223:dbSNP
2157:C/XI
2152:B/IX
1769:and
1707:MeSH
1696:OMIM
1685:9-CM
1578:PMID
1545:PMID
1504:PMID
1465:PMID
1436:PMID
1391:PMID
1358:PMID
1312:PMID
1206:PMID
1166:PMID
1148:ISSN
1107:PMID
1099:ISSN
1036:PMID
987:PMID
979:ISSN
894:PMID
845:PMID
794:PMID
759:PMID
724:PMID
708:JAMA
689:PMID
644:PMID
575:and
508:oral
468:MnlI
460:MnlI
452:aPTT
399:lung
360:exon
352:gene
340:gene
305:clot
252:6025
240:6025
228:6025
178:Gene
2049:TTP
2032:ITP
1874:DIC
1723:154
1681:ICD
1669:ICD
1654:ICD
1537:doi
1496:doi
1457:doi
1426:PMC
1416:doi
1383:doi
1379:126
1348:doi
1344:130
1304:doi
1300:112
1257:Id.
1198:doi
1156:PMC
1138:doi
1089:doi
1085:107
1026:doi
969:doi
965:100
884:doi
837:doi
825:369
786:doi
751:doi
716:doi
712:277
634:PMC
626:doi
494:or
464:PCR
413:or
378:to
370:'s
354:âa
127:DVT
58:or
2368::
2044:TM
2030::
1721::
1710::
1699::
1688::
1673:10
1661::
1658:11
1606:.
1576:.
1572:.
1551:.
1543:.
1533:98
1531:.
1527:.
1510:.
1502:.
1492:44
1490:.
1471:.
1463:.
1453:22
1451:.
1434:.
1424:.
1410:.
1406:.
1389:.
1377:.
1373:.
1356:.
1342:.
1338:.
1310:.
1298:.
1204:.
1194:71
1192:.
1178:^
1164:.
1154:.
1146:.
1134:11
1132:.
1128:.
1105:.
1097:.
1083:.
1079:.
1065:^
1034:.
1022:19
1020:.
1016:.
993:.
985:.
977:.
963:.
959:.
929:.
892:.
880:13
878:.
874:.
851:.
843:.
835:.
823:.
800:.
792:.
782:24
780:.
757:.
747:73
745:.
722:.
710:.
685:80
683:.
679:.
642:.
632:.
622:51
620:.
616:.
346:.
344:F5
131:PE
109:.
61:F5
1758:e
1751:t
1744:v
1683:-
1671:-
1656:-
1646:D
1621:.
1584:.
1539::
1518:.
1498::
1479:.
1459::
1442:.
1418::
1412:3
1397:.
1385::
1364:.
1350::
1318:.
1306::
1283:.
1247:.
1230:.
1212:.
1200::
1172:.
1140::
1113:.
1091::
1059:.
1042:.
1028::
1001:.
971::
944:.
900:.
886::
859:.
839::
831::
808:.
788::
765:.
753::
730:.
718::
695:.
664:.
628::
528:(
195:1
54:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.